Cargando…

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations

This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The study used a standard 3 + 3 dose es...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Hisashi, Taima, Kageaki, Tanaka, Yoshihito, Itoga, Masamichi, Ishioka, Yoshiko, Nakagawa, Hideyuki, Baba, Keisuke, Hasegawa, Yukihiro, Takanashi, Shingo, Tasaka, Sadatomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2018
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805799/ https://www.ncbi.nlm.nih.gov/pubmed/29423683 http://dx.doi.org/10.1007/s12032-018-1098-3

Ejemplares similares

Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib
por: Taima, Kageaki, et al.
Publicado: (2017)

Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung
por: Itoga, Masamichi, et al.
Publicado: (2021)

Emergency Radiotherapy for Spinal Cord Compression due to Bone Sarcoidosis
por: Tanaka, Yoshihito, et al.
Publicado: (2017)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review
por: Shiratori, Toshihiro, et al.
Publicado: (2020)

Morphological features of bronchiectasis in patients with non-tuberculous mycobacteriosis and interstitial pneumonia
por: Tabe, Chiori, et al.
Publicado: (2022)

Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination: A Case Series
por: Ishioka, Yoshiko, et al.
Publicado: (2022)

Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case report
por: Baba, Keisuke, et al.
Publicado: (2019)

The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study
por: Dobashi, Masaki, et al.
Publicado: (2021)

A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2017)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2020)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
por: Tanaka, Hisashi, et al.
Publicado: (2016)

Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus
por: Itoga, Masamichi, et al.
Publicado: (2015)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: a prospective pilot study
por: Makiguchi, Tomonori, et al.
Publicado: (2023)

Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
por: Makiguchi, Tomonori, et al.
Publicado: (2021)

Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
por: Makiguchi, Tomonori, et al.
Publicado: (2022)

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent
por: Nakamura, Yume, et al.
Publicado: (2023)

Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study
por: Fukushima, Takashi, et al.
Publicado: (2022)

The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review
por: Tanaka, Hisashi, et al.
Publicado: (2013)

Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study
por: Takata, Saori, et al.
Publicado: (2023)

Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR
por: Baba, Keisuke, et al.
Publicado: (2019)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
por: Chen, Dong, et al.
Publicado: (2020)

Prospective exosome‐focused translational research for afatinib study of non‐small cell lung cancer patients expressing EGFR (EXTRA study)
por: Okuma, Yusuke, et al.
Publicado: (2018)

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring EGFR mutations
por: Tanaka, Kentaro, et al.
Publicado: (2017)

Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation
por: Zöchbauer-Müller, Sabine, et al.
Publicado: (2021)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

Afatinib in locally advanced/metastatic NSCLC harboring common EGFR mutations, after chemotherapy: a Phase IV study
por: Thongprasert, Sumitra, et al.
Publicado: (2019)

Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review
por: Zhao, Lingling, et al.
Publicado: (2021)

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
por: Kudo, Kenichiro, et al.
Publicado: (2017)

Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
por: Li, Teng, et al.
Publicado: (2021)

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
por: Liang, Wenhua, et al.
Publicado: (2014)

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
por: Yang, James Chih-Hsin, et al.
Publicado: (2022)

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER2 alterations
por: Torigoe, Hidejiro, et al.
Publicado: (2018)

Successful afatinib rechallenge in a patient with non‐small cell lung cancer harboring EGFR G719C and S768I mutations
por: Masuda, Tomomi, et al.
Publicado: (2020)

Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
por: Ko, Ryo, et al.
Publicado: (2021)

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations
por: Park, Keunchil, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7h427rg9qlmrb0jq2r7eqrclt2